Quality standard for licorice of different sources

doi:10.19803/j.1672-8629.20240286

Abstract

Abstract: Objective To analyze the problems with the quality of Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L., identify obstacles to development and offer solutions. Methods Through talks with enterprises, field investigation, literature research and studies on the quality standard for Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L., the status quo of the Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. industry in Xinjiang, the problems with pharmaceutical standards and opportunities of development were analyzed. Results The rate of defective Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. in the medicinal field was high by the content determination standard specified in the Pharmacopoeia of the People's Republic of China (2020 edition). However, the licorice of three sources contained flavonoids with pharmacological action, so liquiritin alone could not be used as an indicator of quality control. Conclusion It is recommended that the quality standard for Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. be revised to adopt various flavonoid components as the quality evaluation indexes of licorice so as to promote its cultivation in China.

Key words: licorice, Glycyrrhiza inflata Bat., Glycyrrhiza glabra L., liquiritin, quality, standard, origin

CLC Number:

YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240286

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1025

References

[1] ZHOU DL, WANG M, FENG JL, et al.Study on differential metabolites of Glycyrrhiza uralensis Fisch. in different years based on extensive targeted metabonomics[J]. Journal of Pharmaceutical Analysis, 2024, 44(1): 144-157.
[2] BIAN YH, WANG L, ZHANG XY, et al.Current situation and technology improvement of licorice industry chain[J]. Journal of Tianjin University of Traditional Chinese Medicine(天津中医药大学学报), 2020, 39(1): 19.
[3] LI WB, LUO L, CUI J, et al.Research progress on genetic diversity of 3 medicinal glycyrrhiza[J]. Journal of Chinese Medicinal Materials(中药材), 2019, 42(2): 463-469.
[4] XU K, LU JH, LI X, et al.Composition and functions of soil bacterial communities of wild Glycyrrhiza uralensis Fisch. in habitats with different degrees of salinization[J]. Acta Microbiologica Sinica, 2024, 65(5): 1550-1556.
[5] ZHOU G, SHAN LL, WANG YL, et al.Present Situation and prospect of study on quality standard of ethnic medicine in Xinjiang[J]. Chinese Pharmaceutical Affairs(中国药事), 2024, 38(1): 28-34.
[6] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China: VolumeⅠ(中华人民共和国药典一部)[S]. Beijing: China Medical Science Press, 2020: 88-89.
[7] CHEN J, NIE LX, CHENG XL, et al.Qualitative and quantitative analysis of main characteristic components of Glycyrrhiza inflate Bat. with chemometrics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(9): 826-830.
[8] CHEN J, NIE LX, DAI SY, et al.Multivariate statistical analysis of the difference in chemical components between glycyrrhizae radix et rhizoma derived from Glycyrrhiza glabra L. and G. inflata Bat. from Xinjiang[J]. Modern Chinese Medicine(中国现代中药), 2021, 23(12): 2088-2095.
[9] CHEN J, NIE LX, HU XR, et al.Differences of chemical compounds between Glycyrrhiza uralensis Fisch. and Glycyrrhiza glabra L. by UHPLC-Q-TOF-MS/MS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(9): 954-958.
[10] HAN WW, ZHONG Q, ZHANG R, et al.Research progress of active constituents and their mechanism of action in Glycyrrhiza uralensis Fisch.[J]. Chemistry of Life(生命的化学), 2023, 43(12): 1956-1962.

[1]	SHEN Chen, ZHOU Xian, LIU Jianping. Database and Evaluation Methods for Chinese Herb-Drug Interactions [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908.
[2]	YANG Yifan, YANG Yanwei, ZHANG Di, XIE Yin, ZHANG Yong, CHEN Xulin, GAO Sutao, GENG Xingchao, QU Zhe. Quality Control and Test Methods of Human Induced Pluripotent Stem Cells [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 728-734.
[3]	ZHANG Meiwei, LI Keqian, YAO Keyu, ZHU Yan. Current Descriptions of Functions in Package Inserts of Chinese Herbal Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 193-196.
[4]	ZHENG Changhui, MA Lina, HE Ting, GU Yuanyuan, ZHAO Wei, WANG Hongbin, NIU Yuanfei, FU Yao, CHEN Yanjun, CAO Junling. Quality Evaluation and Control of Bupleuri Radix Decoction Pieces Based on ‘Shape-Chemistry-Biology' Sequential Detection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 197-205.
[5]	LIU Bo, YUAN Yanan, WANG Yue, CHENG Shuqian, LU Zhiguo, FAN Huihong, SUN Huimin. Key Technologies for Quality Control of Oligonucleotide Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 1-9.
[6]	LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42.
[7]	SUN Deyang, SUN Jiabei, LI Wenlong, JIA Juanjuan, ZHANG Wenzai, LIU Yan, HUANG Haiwei, YAO Jing. Assignment of Chemical Reference Substance of Aminopolyether -a Key Impurity in Fludeoxyglucose [¹⁸F] Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 43-46.
[8]	JIA Juanjuan, SUN Jiabei, ZHANG Wenzai, SUN Deyang, SHI Yaqin, HUANG Haiwei. Biological Distribution of ^99mTc-DMSA Injection [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 47-52.
[9]	PEI Yusheng, XU Lin, ZHAO Yuxin, CAI Tong, HUA Xiaodong. Low Endotoxin Recovery and Mitigation Strategies [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 72-75.
[10]	LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
[11]	SUN Li, XIE Bin, XU Yanqin. Research progress of sustained and controlled release preparations of Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 949-954.
[12]	YE Anping, WEI Xue, HUANG Mingyue, ZHANG Xianxie, MA Zengchun, GAO Yue. Roles of Yangwei Anshen decoction in improving sleep quality in mouse model of insomnia induced by chronic unpredictable stress [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 771-775.
[13]	SUN Yue, HU Xinyue, LI Jing, ZHANG Wei, DING Xiaoli, ZHANG Hui, LIANG Chenggang. Quality evaluation of desmopressin tablets and injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 632-637.
[14]	DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan. Quality evaluation of insulin glargine injections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.
[15]	HU Xiaozhen, MA Lina, HE Ting, GU Yuanyuan, ZHAO Wei, ZHENG Changhui, YE Zuguang, CAO Junling. Literature research on ancient and modern literature of Dichroae Radix and Shu lacquer [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 587-593.